Squarepoint’s Neurocrine Biosciences NBIX Stock Holding History

Squarepoint’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,300	Closed	-$587K	–	5134
2024 Q4	$587K	Buy	+4,300	New	+$532K	﹤0.01%	3596

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's NBIX Position: Q1 2026 in Review

Squarepoint increased its Neurocrine Biosciences (NBIX) stake by 133% in Q1 2026, buying an estimated $36.9M and bringing the position to 487,953 shares worth $64.3M. The position accounts for 0.08% of the portfolio, ranked #262.

Squarepoint first reported a position in NBIX in Q4 2015 and has held it in 35 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Squarepoint held 487,953 shares of Neurocrine Biosciences worth $64.3M as of Q1 2026.
Squarepoint bought 278,247 Neurocrine Biosciences shares in Q1 2026, an estimated $36.9M.
Neurocrine Biosciences made up 0.08% of Squarepoint's portfolio in Q1 2026, its #262 holding.
Squarepoint first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 35 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.